Abstract: Using one or more parasympathomimetic drugs alone or together, or in combination with one or more alpha agonists to create optically beneficial miosis to temporarily create multifocality in a pseudophakic patient to treat presbyopia. A pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, alone or in combination with or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. A method for creating multifocality in a pseudophakic patient, reducing symptoms of presbyopia in a patient having an eye or both eyes through administering to an eye or eyes a pharmaceutically effective amount of the ophthalmic preparation is also disclosed.

Abstract: Use of topical carbachol in combination with brimonidine to create optically beneficial miosis to temporarily treat presbyopia. A pharmaceutical formulation is used comprising a therapeutically effective amount of carbachol, or a pharmaceutically acceptable salt thereof, in combination with brimonidine, or a pharmaceutically acceptable salt thereof, specifically combined with permeation enhancers and excipients to increase efficacy and reduce ocular surface toxicity and improve tolerability.

Abstract: Using one or more parasympathomimetic drugs alone or together, or in combination with one or more alpha agonists to create optically beneficial miosis to temporarily create multifocality in a pseudophakic patient to treat presbyopia. A pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, alone or in combination with or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. A method for creating multifocality in a pseudophakic patient, reducing symptoms of presbyopia in a patient having an eye or both eyes through administering to an eye or eyes a pharmaceutically effective amount of the ophthalmic preparation is also disclosed.

Abstract: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

Abstract: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

Abstract: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

Abstract: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

Abstract: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

Abstract: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

Abstract: Selective inhibitors for COX-2 were discovered to prevent the reactivation of viruses that cause latent infections such as herpes simplex virus (HSV-1 and HSV-2). Using mice with a latent infection of HSV, which is subject to reactivation when heat-stressed, a selective COX-2 inhibitor (celecoxib) was shown to significantly suppress viral reactivation in the eye when the inhibitor was administered either by intraperitoneal injection or orally. Acetylsalicylic acid, a nonspecific cyclooxygenase inhibitor, was also found to suppress viral reactivation in this heat-stress mouse model. The COX-2 specific inhibitor, celecoxib, was more effective in preventing viral recurrence than was the nonspecific cyclooxygenase inhibitor aspirin. The use of selective inhibitors of COX-2 to inhibit the recurrence of latent viral infections will be more effective and have fewer side effects than the nonspecific inhibitors. In addition, selective inhibitors of COX-2 can be combined with other known antiviral compounds.

Abstract: An intracorneal astigmatic, rectangular onlay has been discovered that can correct for astigmatism by physically adjusting the shape of the cornea. This astigmatic onlay can be narrow or wide and can easily be placed in the stroma of the cornea. The onlay can be placed on top of a laser ablation or on a spherical lens, which in turn was implanted either under a tissue flap or in a stromal pocket. The astigmatic onlay is easy to position at precisely the correct angle to compensate for the astigmatism-causing meridional distortion. This invention greatly increases the utility and practicality of intracorneal spherical lenses and makes it easy to position the astigmatic correcting ridge at precisely the correct angle to compensate for the astigmatism. The invention greatly decreases the inventory needed to compensate for both spherical and astigmatic corrections. For example, spherical corrections from +5 D to −5 D at 0.

Abstract: An artificial tear suspension system is provided which includes bioerodible mucin-type particles, lipid-type material and aqueous-type material. The bioerodible mucin-type particles are suspended in either the lipid-type material or the aqueous-type material or both. The system provides all of the components of the natural tear film layers, and thus when administered to the eye provides an effective tear film which mimics the natural tear film.

Abstract: An ophthalmic treatment system is provided which includes three-dimensional particles of bioerodible material suspended in a liquid carrier or ointment carrier having a pH acceptable to the eye. The particles are at least 0.5 mm in greatest dimension and are not greater than 0.4 mm to 0.7 mm in smallest dimension when disposed in the ocular environment. The treatment system provides reliable, prolonged continuous treatment without irritating the eye.

Abstract: An ophthalmic drug delivery system is provided which includes at least one particle of bioerodible material, and a liquid or ointment carrier which includes ophthalmic drug to be delivered to the ocular area. A process of making the system and a method of treatment are also provided.

Abstract: An ophthalmic drug delivery system is provided which includes at least one particle of bioerodible material, and a liquid or ointment carrier which includes ophthalmic drug to be delivered to the ocular area. A process of making the system and a method of treatment are also provided.

Abstract: A system useful for holding a lens device is disclosed and comprises: a chamber having a hollow interior space therein; a seal element capable of being placed in association with said chamber to substantially seal said interior space from the environment surrounding said chamber; a carrier assembly sized and adapted to carry a lens device and to be placed in said interior space; and an absorbent member located in said interior space and capable of carrying a material which is released into said interior space over a period of time.

Abstract: A trephine for cutting a groove in the cornea of an eye comprising a fixation member and a shaft having first and second blades mounted thereon. The fixation member includes a bearing, and the shaft is receivable within the bearing. The fixation member can be affixed to the eye, and the shaft, when received in the bearing, is rotatable in the bearing so that the blades can make cuts in the cornea. By making cuts in the cornea which intersect, a segment of the cornea can be removed to provide the groove.

Abstract: A trephine for cutting a groove in the cornea of an eye comprising a fixation member and first and second shafts having blades mounted thereon. The fixation member includes a bearing, and the shafts are sequentially receivable within the bearing. The fixation member can be affixed to the eye, and the shafts, when received in the bearing, are rotatable in the bearing so that the blades carried by the shafts can make cuts in the cornea. By making cuts in the cornea which intersect, a segment of the cornea can be removed to provide the groove.